Product Description
Irinotecan is a type of chemotherapy. It is also known by its brand name Campto. It is a treatment for cancer that started in the bowel (bowel cancer). This includes the colon and back passage (rectum). (Sourced from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/irinotecan)
Mechanisms of Action: TOP1 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: Fast Track - Pancreatic Cancer *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Adenocarcinoma | Pancreatic Cancer | Oncology Unspecified
Known Adverse Events: Stomatitis | Lymphopenia | Neutropenia | Asthenia | Diarrhea
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czech Republic, Denmark, Finland, France, Georgia, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Mexico, Netherlands, Norway, Peru, Poland, Portugal, Romania, Russia, Serbia, Singapore, Slovakia, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 145
Highest Development Phases
Phase 3: Adenocarcinoma|Cervical Cancer|Colorectal Cancer|Esophageal Cancer|Gastrointestinal Cancer|Neuroendocrine Carcinoma|Pancreatic Cancer|Peritoneal Cancer|Small Cell Lung Cancer|Squamous Cell Carcinoma
Phase 2: Bile Duct Cancer|Biliary Tract Cancer|Bladder Cancer|Brain Cancer|Breast Cancer|Cholangiocarcinoma|Ductal Carcinoma|Embryonal Rhabdomyosarcoma|Gallbladder Cancer|Glioma|Hepatoblastoma|Hepatocellular Carcinoma|Islet Cell Carcinoma|Lung Cancer|Neuroblastoma|Neutropenia|Oncology Solid Tumor Unspecified|Oncology Unspecified|Osteosarcoma|Ovarian Cancer|Pancreatic Ductal Carcinoma|Peripheral Neuroectodermal Tumors, Primitive|Primitive Neuroectodermal Tumors|Rhabdoid Tumor|Rhabdomyosarcoma|Sarcoma|Sarcoma, Ewing|Wilms Tumor
Phase 1: Appendiceal Cancer|Ataxia Telangiectasia|Lyme Disease|Medulloblastoma|Melanoma|Mesothelioma|Mucinous Adenocarcinoma|Mucinous Cystadenocarcinoma|Prostate Cancer|Pseudomyxoma Peritonei
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| STEREOPAC-001 | P2 |
Not yet recruiting |
Adenocarcinoma|Pancreatic Cancer |
2032-10-01 |
|
| MEND-IT | P2 |
Active, not recruiting |
Colorectal Cancer |
2030-05-17 |
|
| 2023-509814-12-00 | P2 |
Not yet recruiting |
Colorectal Cancer |
2030-03-31 |
|
| 2015-003602-16 | P2 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
2029-11-30 |